Ambrose Healthcare Acquires AM-Pharma for Up to €161 Million as ValiRx Flags 5.55% Stake

Ambrose Healthcare acquired AM-Pharma for up to €161 million, adding ilofotase alfa for hypophosphatasia to its rare disease pipeline and a European base in Utrecht. ValiRx, a life science company focused on early-stage cancer therapeutics and women's health, disclosed the deal in an update on its shareholding in Ambrose, Investegate reported on October 21, 2026.

Ambrose's AM-Pharma Deal Terms

Ambrose Healthcare is a private UK pharmaceutical company that acquires and develops late-stage drug candidates for rare diseases with no approved treatment, according to company records. AM-Pharma is a Dutch biopharmaceutical company whose ilofotase alfa has received Orphan Drug Designation for hypophosphatasia from both the FDA and the EMA.

Ambrose acquired 100% of AM-Pharma for up to €161 million, including upfront and milestone payments, GlobeNewswire reported on October 20, 2026. The deal adds ilofotase alfa for hypophosphatasia to Ambrose's pipeline and gives it a European base in Utrecht. No further financial terms were disclosed.

ValiRx's 54.14% owned subsidiary ValiSeek holds 576,000 ordinary shares in Ambrose from an intellectual property licence agreement for VAL401, plus 75,000 ordinary shares from an original option agreement, representing approximately 5.55% of Ambrose's issued share capital. ValiSeek is entitled to clinical and commercial milestone payments of up to £16 million, together with royalties.

Mark Eccleston, CEO of ValiRx, said: "As the third largest shareholder in Ambrose, we're delighted to see the acquisition of this additional clinical stage asset with established positive safety in almost 700 patients."

Ambrose's Pipeline and Funding Record

Ambrose Healthcare was incorporated in October 2022 and launched in early 2023, according to funding records. Its leadership team collectively has over 200 years of combined pharmaceutical experience, and the team has raised £200m and delivered £1 billion of value across previous ventures.

Ambrose's pipeline includes renzapride for cystic fibrosis gastrointestinal symptoms and VAL401 for oncology, targeting orphan drug pathways. The company is pre-revenue and based in Cambridge, with Toby Wilson Waterworth as Founder and Chairman.

Earlier Ambrose and ValiRx Steps

In December 2023, ValiSeek granted Ambrose an exclusive option to license VAL401, a repurposed risperidone formulation, with clinical and commercial milestone payments up to £16 million plus royalties, akta.pro records show.

In June 2025, ValiRx exercised its option to license VAL401 from ValiSeek, securing full global rights to develop and commercialize the oncology candidate in exchange for up to £16 million in clinical and commercial milestones plus royalties and 576,000 ordinary shares issued to ValiRx.

In April 2026, Ambrose strengthened its executive team with five senior appointments ahead of pivotal clinical execution and capital raising, including CFO Ali Elsley and CSO Clarissa Sowemimo-Coker.

AM-Pharma Deal Closing

The acquisition was announced on October 20, 2026, and ValiRx noted the movement in its share price on that date following the announcement.